Athena Countouriotis Turning Point Therapeutics, Inc. (TPTX) insider trading activity

Athena Countouriotis is President & CEO of Turning Point Therapeutics, Inc.. Currently has a direct ownership of 0 shares of TPTX, which is worth approximately $0. The most recent transaction as insider was on Aug 17, 2022, when has been sold 110,959 shares (Common Stock) at a price of $76.0 per share, resulting in proceeds of $8,432,884. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Athena Countouriotis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Date	Transaction	Value	Shares Traded	Shares Held	Form
Aug 17 2022	SELL Sale (or disposition) back to the issuer	$8,432,884 $76.0 p/Share	110,959 Reduced 100.0%	0 Common Stock
Feb 09 2022	SELL Open market or private sale	$107,847 $36.3 p/Share	2,971 Reduced 5.84%	47,930 Common Stock
Feb 09 2022	BUY Grant, award, or other acquisition	-	62,400 Added 36.13%	110,330 Common Stock
Feb 11 2021	SELL Open market or private sale	$1,229,972 $137.55 p/Share	8,942 Reduced 15.12%	50,195 Common Stock
Feb 11 2021	BUY Exercise of conversion of derivative security	$28,614 $3.2 p/Share	8,942 Added 13.13%	59,137 Common Stock
Feb 10 2021	SELL Open market or private sale	$3,464,230 $136.43 p/Share	25,392 Reduced 33.59%	50,195 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	$81,254 $3.2 p/Share	25,392 Added 25.15%	75,587 Common Stock
Feb 09 2021	SELL Open market or private sale	$3,554,484 $138.49 p/Share	25,666 Reduced 33.83%	50,195 Common Stock
Feb 09 2021	BUY Exercise of conversion of derivative security	$82,131 $3.2 p/Share	25,666 Added 25.28%	75,861 Common Stock
Feb 08 2021	BUY Grant, award, or other acquisition	-	22,617 Added 31.06%	50,195 Common Stock
May 21 2020	BUY Open market or private purchase	$249,960 $60.0 p/Share	4,166 Added 13.42%	26,872 Common Stock
Dec 10 2019	BUY Grant, award, or other acquisition	$21,978 $31.13 p/Share	706 Added 3.02%	22,706 Common Stock
Sep 10 2019	BUY Open market or private purchase	$450,000 $45.0 p/Share	10,000 Added 31.25%	22,000 Common Stock
Apr 22 2019	BUY Open market or private purchase	$216,000 $18.0 p/Share	12,000 Added 50.0%	12,000 Common Stock

Also insider at

PASG

Passage BIO, Inc. Healthcare

IOVA

IOVANCE BIOTHERAPEUTICS, INC. Healthcare

Director

BMRN

BIOMARIN PHARMACEUTICAL INC Healthcare

Director

Athena Countouriotis

President & CEO

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TPTX shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Turning Point Therapeutics, Inc. insider buys or sells TPTX shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to Turning Point Therapeutics, Inc.

Track Activities on TPTX

Account